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Invalidation of uncoupling protein 2 (Ucp2) increases glucose utilization and proliferation in normal cells. We
recently reported that cancer cells that overexpress UCP2 become less tumorigenic while switching their metabolism
from glycolysis to oxidative phosphorylation. UCP2 appears to be a key regulator of cellular metabolism with a relevant
function against tumorigenesis.
Metabolic remodeling associated with
cancer is the subject of renewed research
interest that integrates multiple aspects of
bioenergetic adaptation. The maintenance
of mitochondrial function during cell
growth and development is tightly associ-
ated with mitochondria–nuclear crosstalk.
Because of the quantitatively predominant
role of the nuclear genome in mitochon-
dria biogenesis, much attention over the
past several decades has been directed to
the analysis of anterograde regulation.
However, recent studies have revealed that
mitochondria are also engaged in retro-
grade regulation, which can be defined as
cellular responses, mostly changes in
nuclear gene expression, to changes in the
functional state of mitochondria. This ret-
rograde signaling is for the most part an
adaptive response and its outcome is usu-
ally a recasting of metabolic, regulatory,
or stress-related pathways.
Uncoupling protein 2 (UCP2) is a
mitochondrial carrier whose protein
expression is tightly related to changes in
cell proliferation, and as such is a crucial
player in the cascade of mitochondrial
molecular events associated with carcino-
genesis. Indeed, Ucp2 invalidation is asso-
ciated with increased cell proliferation
both in primary embryonic fibroblasts
(MEF) and in activated T cells isolated
from Ucp2¡/¡ mice.1 In our recent report
in Cancer Research2 we showed that direct
manipulation of mitochondrial activity
through expression of this inner mem-
brane carrier induces a feed-forward loop
from mitochondria to the adenosine
monophosphate-activated protein kinase
(AMPK)/hypoxia inducible factor (HIF)
axis that modifies cancer cell proliferation
(Fig. 1). Using different cancer cell lines
that overexpress UCP2, we showed that
UCP2 protein expression level correlates
closely and negatively with tumor prolifer-
ation in vitro and in vivo. This decrease in
proliferation is associated with metabolic
remodeling, i.e., decreased glycolysis and
increased oxidative phosphorylation. We
showed that the antitumor effect of UCP2
is associated with an increase in AMPK
signaling and a decrease in HIF. Our
study indicated that a reduced fumarate
level driven by UCP2 could be the link
between AMPK activation and the signifi-
cant decrease in HIF2-a expression.
Indeed, cancers carrying mutations in
enzymes involved in the tricarboxylic acid
cycle (TCA), specifically succinate dehy-
drogenase (SDH) and fumarate hydratase
(FH), show intracytoplasmic accumula-
tion of fumarate and succinate that inhibits
the prolyl hydroxylase domain proteins
(PHD), thus allowing stabilization of
HIF.3 Furthermore, other studies have
shown that AMPK activity is decreased in
renal cancer cells deficient in FH enzyme,
which also accumulate fumarate.4
Despite the answers provided by our
investigation, several questions remain:
Which metabolite does UCP2 transport?
How is AMPK activated? Does such
UCP2 retrograde signaling apply to all
tumors? Could a UCP2 activator have
beneficial effects on cancer treatment,
either by slowing down cancer progression
or by sensitizing cancer cells to treatment?
UCP2 activity has long been associated
with an uncoupling effect.5 In our study,
UCP2 overexpression does not alter mito-
chondrial membrane potential, or the P/
O ratio between ATP synthesis and oxy-
gen consumption. Instead, UCP2 modi-
fies metabolic substrate orientation
through modulation of metabolite
compartmentalization involved in mito-
chondrial anaplerotic metabolism. More-
over, in support of this hypothesis,
Fiermonte’s laboratory recently showed
that UCP2 protein transports 4-carbon
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metabolites such as aspartate, malate, and
oxaloacetate out of the mitochondria.6
Our results suggest that re-expression
or reactivation of UCP2 may be a winning
therapeutic strategy. However, several
studies have previously shown that UCP2
overexpression in cancer cells was associ-
ated with increased proliferation,7-9
decreased ROS production, and decreased
apoptosis8,9 whereas other studies showed
that UCP2 silencing reduced survival
through increased differentiation and apo-
ptosis.10 However, all of these studies
were performed in cancer cell lines
expressing a high endogenous level of
UCP2, such as colon, breast, and lung
cancer cells. In contrast, our study is the
only one using cancer cells with a low
endogenous UCP2 protein level and in
these cells UCP2 overexpression has an
antiproliferative effect. In fact, microarray
database analysis (www.oncomine.org)
allows the distinction of 2 different types
of cancer on the basis of UCP2 mRNA
expression: cancers with high UCP2
mRNA level such as lymphomas, lung,
breast, and colorectal cancers; and cancers
with low UCP2 mRNA level such as glio-
blastoma, melanoma, prostate, and liver
cancers. This observation may underlie
some metabolic differences between these
2 groups. However, mRNA expression
does not always reflect UCP2 protein level
since UCP2 is translationally regulated
and it would therefore be interesting to
determine whether UCP2 protein level is
concordant with its mRNA expression in
these cancers. Together, these observations
suggest that UCP2 involvement in tumor-
igenesis is cell type-dependent and may
depend on the metabolism exhibited by
normal cells before their transforma-
tion, as reflected by the endogenous
protein level of UCP2. In addition, it
will be important to determine whether
UCP2 protein expression is correlated
with tumor grade, tumor
invasiveness, and energy
metabolism.
Finally, the development
of animal models for differ-
ent cancers, in particular
those with low (e.g., glio-
blastoma) and high (e.g.,
colorectal) UCP2 expres-
sion, is essential in order to
understand whether UCP2
is able to modify tumor
metabolism in vivo and to
determine more precisely
which metabolite is trans-
ported by UCP2. Moreover,
in vivo models will highlight
whether (i) UCP2 function
affects crucial cellular players
in cancer; (ii) UCP2 could
be considered as a biomarker
to distinguish metabolism of
tumors; and, most impor-
tantly, (iii) targeting UCP2
can improve therapeutic
outcomes.
Our study contributes to
the understanding of cancer
metabolism. UCP2 appears
to be an interesting candi-
date in the dialog between
energy metabolism and proliferation.
Moreover, since the mitochondrial activity
of cells is directly associated with their sus-
ceptibility to different agents that induce
cell death (i.e., chemotherapy or radio-
therapy) UCP2 may be a novel target for
sensitization of tumor cells to anticancer
treatments.
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Figure 1. UCP2-induced metabolic reprogramming involves the HIF/AMPK axis to inhibit proliferation of cancer
cells. Tumor cells with low protein levels of endogenous uncoupling protein 2 (UCP2) proliferate rapidly and
express high levels of hexokinase 2 (HK2) and pyruvate kinase isoform 2 (PKM2) enzymes. In these cells, UCP2 over-
expression triggers a metabolic reprogramming favoring oxidative metabolism with increased expression of pyru-
vate dehydrogenase (PDH) and oxidative phosphorylation (OXPHOS), and conversely decreased expression of HK2
and PKM2. This reprogramming is associated with decreased hypoxia inducible factor (HIF) signaling and increased
adenosine monophosphate-activated protein kinase (AMPK) activity. This feed-forward loop from mitochondria to
AMPK/HIF axis driven by UCP2 decreases the tumorigenic properties of tumor cells.
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